Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

British Journal of Haematology

Volumn 148, Issue 3, 2010, Pages 386-393

  Alatrash, Gheath ^a   Albitar, Maher ^b   O'Brien, Susan ^c   Wang, Xuemei ^a   Manshouri, Taghi ^c   Faderl, Stefan ^c   Ferrajoli, Alessandra ^c   Burger, Jan ^c   Garcia Manero, Guillermo ^c   Kantarjian, Hagop M ^c   Lerner, Susan ^c   Keating, Michael J ^c   Wierda, William G ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

CD20; CD52; CLL; Cyclophosphamide and rituximab; Fludarabine; Salvage

Indexed keywords

CD20 ANTIGEN; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; GLYCOPROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VIDARABINE;

EID: 74049101675     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07965.x     Document Type: Article

References (20)

1. Albitar, M., Do, K.A., Johnson, M.M., Giles, F.J., Jilani, I., O'Brien, S., Cortes, J., Thomas, D., Rassenti, L.Z., Kipps, T.J., Kantarjian, H.M. Keating, M. (2004) Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer, 101, 999 1008.
2. Belov, L., de la Vega, O., dos Remedios, C.G., Mulligan, S.P. Christopherson, R.I. (2001) Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Research, 61, 4483 4489.
3. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990 4997.
4. Elsner, J., Hochstetter, R., Spiekermann, K. Kapp, A. (1996) Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood, 88, 4684 4693.
5. Giles, F.J., Vose, J.M., Do, K.A., Johnson, M.M., Manshouri, T., Bociek, G., Bierman, P.J., O'Brien, S.M., Keating, M.J., Kantarjian, H.M., Armitage, J.O. Albitar, M. (2003) Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. British Journal Haematology, 123, 850 857.
6. Gilleece, M.H. Dexter, T.M. (1993) Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood, 82, 807 812.
7. Golay, J.T., Clark, E.A. Beverley, P.C. (1985) The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. Journal of Immunology, 135, 3795 3801.
8. Jilani, I., Keating, M., Day, A., William, W., Kantarjian, H., O'Brien, S., Giles, F.J. Albitar, M. (2006) Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies. Clinical and Laboratory Haematology, 28, 325 331.
9. Keating, M.J., O'Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., Koller, C., Wierda, W., Detry, M.A., Lynn, A. Kantarjian, H. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4079 4088. (Pubitemid 46211313)
10. Kehrl, J.H., Riva, A., Wilson, G.L. Thevenin, C. (1994) Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunology Today, 15, 432 436.
11. Manshouri, T., Do, K.A., Wang, X., Giles, F.J., O'Brien, S.M., Saffer, H., Thomas, D., Jilani, I., Kantarjian, H.M., Keating, M.J. Albitar, M. (2003) Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood, 101, 2507 2513.
12. Ravandi, F. O'Brien, S. (2006) Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Investigation, 24, 718 725.
13. Riley, J.K. Sliwkowski, M.X. (2000) CD20: a gene in search of a function. Seminars in Oncology, 27, 17 24.
14. Rowan, W., Tite, J., Topley, P. Brett, S.J. (1998) Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology, 95, 427 436.
15. Salisbury, J.R., Rapson, N.T., Codd, J.D., Rogers, M.V. Nethersell, A.B. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. Journal of Clinical Pathology, 47, 313 317.
16. Tam, C.S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.A., Thomas, D.A., Cortes, J., Lerner, S. Keating, M.J. (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood, 112, 975 980.
17. Taylor, M.L., Noble, P.W., White, B., Wise, R., Liu, M.C. Bochner, B.S. (2000) Extensive surface phenotyping of alveolar macrophages in interstitial lung disease. Clin Immunol, 94, 33 41.
18. Tedder, T.F. Engel, P. (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology Today, 15, 450 454.
19. Wierda, W., O'Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.A., Cortes, J., Koller, C., Beran, M., Ferrajoli, A., Giles, F., Lerner, S., Albitar, M., Kantarjian, H. Keating, M. (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4070 4078. (Pubitemid 46211312)
20. Wierda, W., O'Brien, S., Faderl, S., Ferrajoli, A., Wang, X., Do, K.A., Garcia-Manero, G., Thomas, D., Cortes, J., Ravandi-Kashani, F., Giles, F., Lerner, S., Kantarjian, H. Keating, M. (2006) A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer, 106, 337 345.